Prot #MEI-005: A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients with Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone

Project: Research project

Project Details

Effective start/end date3/7/143/7/17


  • SCRI Development Innovations, LLC (Prot #MEI-005 // Prot #MEI-005)
  • MEI Pharma, Inc. (Prot #MEI-005 // Prot #MEI-005)